Merck (NYSE: MRK) Falls 5% Following Data from Summit Therapeutics (NASDAQ: SMMT)Summit to Initiate HARMONi-7, a Phase III Trial in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE